ACQUISITIONS (Tables)

12 Months Ended

Mar. 31, 2015

Schedule of acquisition date fair value of the purchase consideration

In November 2014, Abaxis, through its wholly-owned subsidiary, entered into Share Purchase Agreements pursuant to which, Abaxis acquired 100% of the outstanding stock of Quality Clinical Reagents Limited (“QCR”) and Trio Diagnostics (Ireland) Ltd (“Trio”), both based in the United Kingdom. QCR and Trio are distributors of laboratory instrumentation and consumables to the veterinary profession in the United Kingdom. Our primary reason for the acquisitions was to continue servicing and supplying Abaxis veterinary products to our customer base. The acquisition date fair value of the purchase consideration was $6.5 million, which included the following (in thousands):

Cash	$	3,196
Installment payment obligations (1)		2,336
Settlement of preexisting business relationship at fair value		931
Total	$	6,463

(1)	The installment payment obligation is denominated in GBP and the amount in the table above is based on the exchange rate at the acquisition date.

Schedule of recognized identified assets acquired and liabilities assumed

The following table summarizes the acquisition date fair value of net tangible assets acquired and liabilities assumed from QCR and Trio (in thousands):

	Fair Value
Net tangible assets acquired	$	5,248
Intangible assets
Customer relationships		1,535
Tradename		16
Deferred tax liabilities		(336	)
Total	$	6,463